Drug Profile
CIGB 50
Alternative Names: Anti-IL-15-vaccine-CIGB; Anti-interleukin-15-vaccine-CIGB; CIGB50Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class Vaccines
- Mechanism of Action Advanced glycosylation end product modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Cuba (SC, Injection)
- 24 Feb 2016 Phase-I clinical trials in Rheumatoid arthritis in Cuba (SC) prior to February 2016 (CIGB-Heber Biotech pipeline, February 2016)
- 31 Dec 2015 Immunogenicity data from a preclinical trial released by CIGB (CIGB-Heber Biotech presentation, 2014-2015)